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Objectives. This study was performed to determine whether 
intravenous injection of a sonicated albumin echocardiographic 
contrast agent (Albunex) improved the quality of the trans- 
thoracic pulmonary venous flow Doppler signal. 
Background. Previous studies have shown that transesophageal 
echocardiography provides pulmonary venous flow Doppler sig- 
nals superior in quality to those seen with transthoracic echocar- 
diography, which are of limited quality in up to 25% of patients. 
Methods. Twenty-one patients underwent ransthoracic pulsed 
wave Doppler examination of pulmonary venous flow before, 
during and after two doses of Albunex ranging from 0.08 ml/kg 
(low dose) to 0.22 ml/kg (high dose). In addition, five patients 
underwent transesophageal examination of pulmonary venous 
flow before and after a 0.08.ml/kg dose of Albunex. The efficacy of 
the contrast injection was determined using a score that graded 
the quality of the three components of the pulmonary venous 
Doppler signal from 0 to 3 (0 = no visible signal; 3 = optimal 
signal). 
Results. Aibunex enhanced the quality of the pulmonary venous 
Doppler signal from baseline (score 3.9 -+ 1.8 [mean -+ SD]) and 
at both low (score 5.1 -+ 2.2, p < 0.05) and high doses (score 5.6 -+ 
2, p < 0.001). Transthoracic pulmonary venous flow velocities 
were increased, and peak flow velocity ratios were unchanged, 
after injection of contrast agent. The contrast-enhanced variables 
showed good agreement with transesophageal flow velocities. 
Conclusions. Aibunex improves the quality of the transthoracic 
pulmonary venous Doppler signal, thus allowing improved accu- 
racy of measurement. This approach appears to be effective for 
increasing the quality of data obtained from the transthoracic 
examination. 
(J Am CoU Cardiol 1995;26:1741-6) 
The pattern of pulmonary venous flow as assessed by pulsed 
Doppler echocardiography has proved useful in the analysis of 
diastolic filling and dysfunction, assessment of mitral valve 
disease and estimation of left atrial pressure (1-8). Although 
initial studies were performed with transthoracic echocardiog- 
raphy (1,9), more recently it has been shown that transesoph- 
ageal echocardiography provides significantly better qualiv 
tracings, allowing improved qualitative and quantitative anal- 
ysis of the different waves of the pulmonary venous flow (10). 
However, because transesophageal echocardiography is per- 
formed in a minority of patients undergoing an echocardio- 
graphic examination, its application in the assessment of 
pulmonary venous flow is limited. Although the majority of 
patients are examined with transthoracic echocardiography, 
pulsed Doppler assessment of pulmonary venous flow is inad- 
equate in up to 27% of patients (11). A technique that 
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improves the quality of the transthoracic pulmonary venous 
flow Doppler signal would be of benefit by providing additional 
information on diastolic and mitral valve function in patients 
with transthoracic echocardiographic examination results of 
limited quality. 
Sonicated albumin microbubbles have been found to accu- 
rately mimic red blood cell flow in the microcirculation (12) 
without significant effects on systemic hemodynamic variables 
(13). These microbubbles should also act as acoustic reflectors, 
thus increasing the strength of the returning Doppler signal. 
After intravenous injection, sonicated albumin microspheres 
achieve transpulmonary passage in a majority of patients (14), 
but the effects of this contrast agent on the pulmonary venous 
flow Doppler signal are unknown. 
The objectives of this study were to determine whether 
intravenous injection of Albunex increased the quality of the 
transthoracic pulmonary venous flow Doppler signal and to 
assess whether a greater number of studies were suitable for 
quantitative analysis than with the standard transthoracic 
pulsed Doppler study. 
Methods  
Study patients. The study group included 21 subjects (16 
men, 5 women; mean [_+SD] age 64 _+ 16 years, range 32 to 
88). Patients ---18 years old who were in sinus rhythm at the 
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time of the examination were invited to participate in the 
study. Subjects were excluded from the study for either of 
the following criteria: 1) history of allergy or reaction to blood 
products, and 2) women of child-bearing potential. The study 
protocol was approved by the Human Studies Committee of 
the Massachusetts General Hospital, and all subjects gave 
written informed consent before participating in the study. 
Contrast agent. Albunex (Molecular Biosystems, Inc.) is a 
commercially produced agent made from 5% sonicated human 
serum albumin that is approved for use with indications of 
ventricular opacification and endocardial border enhance- 
ment. This echocardiographic contrast agent contains air-filled 
albumin microspheres with a mean diameter of 3 to 5 p~m. 
Albunex administration procedure. Injections were per- 
formed through a three-way stopcock and a 19-gauge needle 
into an 18-gauge forearm or antecubital fossa vein angiocath- 
eter. An initial injection of Albunex was given at a dose of 
0.08 ml/kg (low dose), immediately followed by 10 ml of 
isotonic saline. At a minimum of 5 min later, a second injection 
of 0.14 to 0.22 ml/kg (high dose), immediately followed by 10 
ml of isotonic saline, was administered. 
Transthoracic echocardiographic examination. All pa- 
tients had a complete two-dimensional and Doppler color flow 
study with a Hewlett-Packard Sonos 1000 and a 2.5-MHz 
phased-array transducer. Pulsed wave Doppler ultrasound 
examination of the pulmonary venous flow was performed in 
the left lateral decubitus position from the apical four-chamber 
view during quiet respiration. Color Doppler was utilized to 
optimize maximal pulmonary venous flow, and then the sample 
volume was placed 0.5 to 1.0 cm into the right upper pulmo- 
nary vein. The gain, intensity and reject settings of the instru- 
ment were optimized at the baseline study and left unchanged 
during the contrast injections. The high-pass filter was mini- 
mized, and baseline pulmonary venous flow recordings were 
made on both videotape and paper at a speed of 100 mm/s. 
Simultaneous two-dimensional echocardiography in the 
apical four-chamber view was performed at the time of con- 
trast injections. Immediately on identifying contrast medium in 
the right heart, pulsed wave Doppler interrogation fthe right 
upper pulmonary vein was commenced and recorded for 2 rain. 
Transesophageal echocardiographic examination. A sub- 
set of five patients had transesophageal valuation of the 
pulmonary venous flow immediately after the transthoracic 
examination. All studies were performed in the same left 
lateral decubitus position as the transthoracic study to avoid 
changes in the pulmonary venous velocities related to the 
effects of a change in position (15). After topical anesthesia 
of the pharynx and light sedation with intravenous midazo- 
lain, the transesophageal probe (Hewlett-Packard Om- 
niplane) was introduced into the esophagus. Initially, in the 
longitudinal view, the right upper pulmonary vein was 
imaged, and optimal alignment of the Doppler beam with 
this vein was obtained by lateral rotation of the probe and 
adjustment of the Omniplane transducer. The sample vol- 
ume was placed 0.5 to 1 cm into the orifice of the right upper 
pulmonary, vein to obtain optimal spectral display of all 
components of the pulmonary venous flow (10). Filters were 
set to a minimum and gain settings optimized, then left 
unchanged for the baseline and contrast studies. After a 
baseline recording of the pulmonary venous flow, an addi- 
tional low dose (0.08 ml/kg) of Albunex (total dose did not 
exceed 0.30 ml/kg) was injected, followed by 10 ml of 
isotonic saline as previously described. On observing the 
appearance of contrast in the right upper pulmonary vein, 
pulsed wave Doppler interrogation of the pulmonary venous 
flow was recorded at a speed of 100 mm/s for 2 min. 
Doppler analysis and timing. Analysis of the Doppler 
velocity recordings was performed off-line with a Doppler 
analysis package (Sony Cardiologic Analysis System, Sony 
Medical Electronics). Measurements of the peak flow velocity 
and time velocity integral were made during forward systolic, 
diastolic and atrial reverse flow, as previously described (2). At 
least three consecutive cardiac cycles were measured and 
averaged for quantitation. When there was biphasie systolic 
flow, the higher of the two peaks was measured. 
Doppler velocities after contrast injection. Early after con- 
trast injection there was marked spectral distortion and signal 
enhancement that prevented i entification of the modal Dopp- 
ler velocity. Measurements were performed immediately after 
the signal intensity had decreased to the point at which the 
velocity envelope could be accurately traced. The time of this 
measurement was recorded. 
Contrast effect iming. The time from contrast injection to 
appearance in the right heart, time to enhancement of the 
pulmonary venous ignal, duration of spectral distortion, time 
of optimal signal quality and duration of contrast effect were 
recorded for all injections. 
Interobserver variability. The reproducibility of measure- 
ments was assessed by two observers who performed measure- 
ments of peak systolic and diastolic velocities and systolic and 
diastolic time velocity integrals over 20 cardiac cycles. The 
interobserver variability was expressed as the standard evia- 
tion of the mean difference in the observations. 
E~cacy measures. The quality of the contrast effect was 
assessed by an independent observer in blinded manner who 
reviewed and graded the paper recordings of all Doppler 
velocity profiles in random order. The three waves of the 
pulmonary venous flow profiles were rated as follows: 0 = 
unmeasurable; 1 = limited quality but measurable; 2 = good; 
3 = optimal. The scores for the three components were 
summed to give an overall score of the Doppler signal quality. 
A measurable study was defined as having a minimal score of 
1 for each of the three waves of the flow velocity profile. As an 
additional ssessment of the quality of the Doppler signal, the 
presence of a biphasic systolic flow wave was recorded at all 
stages. 
Statistical analysis. Results are expressed as mean value + 
SD. Comparisons of categoric variables were made with the 
Fisher exact probability test. Comparisons between pulmonary 
venous flow velocities, integrals and ratios at different stages 
were made with multivariate analysis of variance with planned 
comparisons. Results were considered significant at p < 0.05. 
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Table 1. Timing of Sonicated Albumin Contrast Effects 
Low Dose High Dose 
(0.08 ml/kg) (up to 0.22 ml/kg) 
Time intervals (s) 
IV-RH 4.5 + 2.2 4.8 _+ 2.0 
RH-PV 4.5 + 1.4 4.6 + 1.6 
RH-ME 33 + 20 38 _+ 17 
Duration of effect (s) 
Spectral distortion 23 = 15 30 -+ 15' 
Measurable period 25 : 18 26 _+ 16 
Contrast enhancement 53 : 28 61 _+ 27"~ 
*p < 0.001, ~p < 0.05 versus low dose study. Data presented are mean 
value -+ SD. IV-RH = time from intravenous injection to right heart; RH-ME : 
time from right heart o measurement of pulmona~ venous velocities; RH-PV : 
time from right heart to pulmonary, venous flow enhancement. 
Resu l ts  
Timing of contrast effects (Table 1). The transit imes of 
contrast medium from the peripheral injection site to the right 
heart and from the right heart to the pulmonary veins were 
similar for the low and high dose studies. Spectral distortion 
and amplification of noise levels were seen with all trans- 
thoracic contrast Doppler studies in the early phase of the 
pulmonary venous flow recording, with a longer period of 
distortion for the high dose than the low dose studies (30 _+ 
15 s vs. 23 _+ 15 s, p < 0.001). Measurements of Doppler 
velocities were made immediately after cessation of spectral 
distortion, which occurred at 33 _+ 20 s (low dose) and 38 + 
17 s (high dose) after the first appearance ofcontrast medium 
in the right heart. The total duration of contrast enhancement 
of pulmonary venous flow was longer in the high dose than the 
low dose studies (61 _+ 27 s vs. 53 + 28 s, p < 0.05). The 
optimal measurement period, from the end of spectral distor- 
tion to the end of discernible contrast effect, was similar at both 
dosages. 
Efficacy of contrast medium on pulmonary venous flow 
Doppler signal quality (Table 2). There was a significant 
increase in the quality of the pulmonary venous flow Doppler 
signal with injection of Albunex (Fig. 1). Quality scores were 
higher in the low dose (5.1 _+ 2.2, p < 0.05) and high dose 
studies (5.6 _+ 2.0, p < 0.001) than at the baseline transthoracic 
study (3.9 _+ 1.8). High dose Albunex produced an increase in 
the frequency of a detectable biphasic systolic wave from 33% 
at baseline to 67% (p < 0.05). At baseline, 71% of studies were 
Table 2. Effects of Increasing Concentrations of Albunex on 
Transthoracic Pulmonary Venous Flow Doppler Signal Quality in 
21 Subjects 
Low Dose High Dose 
Baseline (0.08 ml/kg) (up to 0.22 ml/kg) 
Quality score (mean _+ SD) 3.9 z 1.8 5.1 + 2.2 x 5.6 _+ 2.0~ 
Biphasic systolic wave (%) 33 48 67* 
Measurable studies (%) 71 81 90 
Unmeasurable studies (no.) 6 4 2* 
*p < 0.05, ?p < 0.001 versus baseline study. 
S 0.6 m/s- 
- 0.6 m/s 
Figure l. Transthoracic pulsed wave Doppler pulmonary venous flow 
profiles from the right upper pulmonary vein. A, Baseline profile with 
definition of a single systolic (S) wave and diastolic (D) and atrial 
reversal (AR) waves. B, Profile after a 0.08-ml/kg contrast injection 
demonstrating i creased flow velocities. Note that the systolic wave 
now appears biphasic. 
measurable compared with 81% with low dose and 90% with 
high dose contrast medium. The number of unmeasurable 
studies at baseline was reduced from six to two after high dose 
Albunex (p < 0.05), and only one subject did not have 
enhancement of the pulmonary venous flow Doppler signal. 
Effects of contrast medium on transthoracic pulmonary 
flow velocities (Table 3). Fifteen patients had transthoracic 
Doppler studies that were measurable atbaseline and at both 
doses of Albunex. Peak systolic and diastolic flow velocities 
were increased compared with baseline transthoracic velocities 
at both doses of contrast medium. High dose Albunex pro- 
duced a 19% increase in peak systolic velocity and a 16% 
increase in peak diastolic velocity compared with that at 
baseline. Increases in the peak atrial velocity and systolic and 
diastolic flow integrals were observed with high dose contrast 
medium only. The peak systolic/peak diastolic and peak dia- 
stolic/peak atrial ratios were unchanged with both doses of 
Albunex from those at baseline. 
Differential effect of contrast medium on transthoracic and 
transesophageal pulmonary venous flow velocities (Table 4). 
Five subjects had measurable transthoracic and transesopha- 
geat study results. In three of the five transesophageal studies, 
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Table 3. Effects of Increasing Concentrations of Albunex on 
Transthoracic Pulmonary Venous Flow Doppler Velocity in 15 
Subjects 
Low Dose High Dose 
Baseline (0.ll8 ml/V,g) (up to 0.22 ml/kg) 
Peak S (cm/s) 53 ~ 15 50 - 16' 64 _+ 16) 
Systolic flow integral (cm) 13 -- 4 15 -_ 4 16 + 4* 
Peak D (cm/s) 45 m 11 4 t) + 14:~ 51 + l I "t 
Diastolic flow integral (cm) Ill +_ 3 It) _+ 3 11 _+ 3§ 
Peak A (cm/s) 27 _+ 4 28 + 5 29 _+ 4§ 
A wave integral (cm) 2.3 _+ 0.6 2.3 + 0.5 2.5 _+ 0.6 
Peak S/Peak D 1.3 + 0.5 1.3 + 0.5 1.3 + 0.5 
Peak D/Peak A 1.7 _+ 0.5 1.8 + 0.6 1.8 _+ 0.5 
*p < 0.005, tp < 0.0001, Sp < 0.01, §p <: 0.05 versus baseline study. Data 
presented are mean value _+ SD. A = atrial reverse flow: D = diastolic flow: S = 
systolic flow. 
0.6 rn/ l -  
there was minor spectral distortion and noise early after 
Albunex injection, but to a much lesser degree than was 
observed in the transthoracic recordings for the same patients. 
As seen in the total study group, Albunex produced in- 
creases in transthoracic peak systolic and diastolic velocities 
compared with baseline values. In contrast, transesophageal 
Doppler velocities appeared unchanged after low dose contrast 
medium (Fig. 2). Yransesophageal baseline peak velocities and 
time-velocity integral measurements were similar to those after 
injection of contrast medium. 
Transthoracic baseline peak velocities were all significantly 
lower than baseline transesophageal velocities, suggesting that 
the transthoracic technique systematically underestimated the 
true pulmonary flow peak velocities. However, there were no 
differences in peak velocities and flow velocity integrals be- 
tween the transthoracic high dose contrast and baseline trans- 
esophageal stages, suggesting that high dose contrast medium 
combined with transthoracic Doppler enabled etermination 
of the true velocities. The peak systolic flow/peak diastolic flow 
ratio and peak diastolic flow/peak atrial reverse flow ratio were 
similar across all five stages in this group. 
The transesophageal tracings (recorded at an average sam- 
ple depth of 3.6 cm) were of superior quality to the trans- 
Figure 2. Yransesophageal pulsed wave Doppler pulmonary venous 
flow profiles from the right upper pulmonary vein. A, Baseline profile 
with biphasic systolic (S), diastolic (D) and atrial reversal (AR) waves. 
B, Profile after a 0.08-ml/kg contrast injection showing no change in 
flow velocities, with a minor increase insignal noise. 
thoracic contrast studies (recorded at an average depth of 
16 cm), with better definition of Doppler velocities and less 
spectral broadening and noise than was observed with the 
transthoracic contrast studies. 
Observer variability. Interobserver variability for both 
peak systolic and diastolic velocities was 2 cm/s. The variabil- 
Table 4. Transthoracic and Transesophageal Echocardiographic Pulmonary Venous Flow Doppler Velocity With Low and High Dose Albunex 
in Five Subjects 
Transthoracic Transesophageal 
Baseline 
Low Dose High Dose Low Dose 
(0.08 ml/kg) (0.14 ml/kg) Baseline (0.08 mlikg) 
Peak S (cm/s) 54 - 17 02 ± 16" 67 + 18t 68 -+ 24:~ 68 _+ 24:]: 
Systolic flow integral (cm) 12 + 2 14 ~ 2 14 +_ 3 12 -+ 2 12 _+ 3 
Peak D (cm/s) 42 L 7 47 ~- (~' 50 +- 6§ 50 -+ 5:[: 49 --+ 6,- +
Diastolic flow integral (cm) '9 + 2 t# -~ 1 10 + 2 8 -+ I 8 _+ 1 
Peak A (cm/s) 22 + 3 24 - 4 26 _+ 4 28 _+ 5~: 27 -+ 5 
A wave integral (cm) 15) ~ 0.3 2 _- I).fl 2 _- 0.5 2.3 -+ 0.6* 2.2 _+ 0.6* 
Peak S/Peak D 1.3 ~ 0.6 1.4 - tl.5 1.5 +_ 0.7 1.4 -+ 0.6 1.6 _+ 0.4 
Peak D/Peak A 1.9 z 0.7 2 _- 0.6 2 _+ 0.5 1.8 -+ 0.5 1.8 _+ 0.5 
*p < 0.01, tp < 0.[)005, ~p < 11.05. §p < 0.005 ~ersus transthuracic baseline study. Data presented are mean value _+ SD. Abbreviations as in Table 3. 
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ities for the systolic and diastolic flow velocity integrals were 
0.7 and 0.4 cm, respectively. 
Discuss ion  
Intravenous injection of sonicated albumin is currently 
indicated for ventricular opacification and endocardial border 
enhancement. The present study reports an additional use for 
Albunex that can easily be performed when evaluating ventric- 
ular function with this agent. Intravenous injection of Albunex 
improves the quality of the transthoracic pulmonary venous 
flow Doppler signal. Analysis of pulmonary venous flow is an 
important method of deriving information i addition to that 
available from evaluating mitral inflow velocities when assess- 
ing left ventricular filling and diastolic function (2,16). 
In the present study we found that the quality of the 
enhanced transthoracic Doppler signal approached that ob- 
tained with transesophageal chocardiography, with the advan- 
tage of being a less invasive technique. In addition, this 
enhancement of the signal resulted in improved accuracy of 
the transthoracic technique. The results of the present study 
also delineate the optimal period for analyzing the pulmonary 
venous flow Doppler signal. 
Spectral noise. Early in the recording of the contrast- 
enhanced pulmonary venous flow Doppler signal, there were 
marked increases in signal intensity and noise. This increase 
was manifested aslarge excursions in the spectral display, with 
loss of the discrete spectra of the pulmonary venous flow 
velocities. This spectral distortion appeared to be temporally 
related to the concentration f microbubbles encountered by
the Doppler beam and was more intense and of longer 
duration with high dose contrast medium. The transthoracic 
contrast studies had worse spectral distortion and noise than 
the transesophageal studies, which is a consequence of noise 
levels being proportional tothe square of the distance from the 
transducer toDoppler eflector (17). 
This period of spectral distortion, which ranged from a 
mean of 23 to 30 s, provides an opportunity oimage the heart 
and evaluate left ventricular function with contrast enhance- 
ment of the endocardial borders before switching to pulsed 
Doppler evaluation of the pulmonary veins. In this way, 
advantage can be taken of the presence of the contrast agent in 
assessing more than one variable of cardiac function during the 
examination. 
Evaluation of pulmonary venous flow quality. The present 
study demonstrated that injection of Albunex improved the 
quality of the transthoracic pulmonary venous Doppler flow 
signal, reflected by an increase in the quality score and 
frequency of a biphasic systolic wave. Previous transthoracic 
studies (18,19) have found biphasic systolic waves in 30% to 
37% of subjects, similar to our finding of 33% at the baseline 
study. We found that high dose contrast medium increased the 
frequency of a biphasic systolic wave to 67% of subjects, which 
is similar to the 73% reported with transesophageal chocar- 
diography by Castello et al. (10). 
At baseline transthoracic e hocardiography, wefound that 
71% of the studies were measurable and that the most 
common reason for an incomplete study was the absence of a 
measurable atrial (A) wave. These findings are similar to those 
of Klein et al. (11), who were able to analyze the pulmonary 
venous flow profiles in 73% of 117 subjects by means of 
transthoracic e hocardiography. With high dose contrast me- 
dium, we obtained measurable studies in 19 (90%) of our 21 
subjects, less than that reported (3) for transesophageal stud- 
ies, up to 100% of which are measurable. 
The unmeasurable cases point out potential limitations of 
this technique. After high dose contrast medium, the number 
of subjects with unmeasurable studies was reduced to two, both 
of whom had poor-quality wo-dimensional studies at baseline. 
One patient had severe chronic obstructive pulmonary disease, 
moderate pulmonary hypertension a d no contrast enhance- 
ment of the pulmonary venous flow signal. The second patient 
had pulmonary fibrosis and mild pulmonary hypertension with 
enhancement of the pulmonary venous flow signal, but no 
measurable A wave. Our findings of limited improvement in 
the Doppler signal with contrast medium in these two subjects 
are consistent with either poor imaging related to their pulmo- 
nary disease or decreased passage of contrast medium through 
the lungs, possibly due to an increased ecay rate of the 
Albunex microspheres related to pulmonary hypertension (20). 
Contrast effects on pulmonary venous flow velocities. Pre- 
vious investigators (21) have reported a tendency for trans- 
thoracic echocardiography to underestimate true pulmonary flow 
velocities as determined by transesophageal chocardiography. 
The observation that the velocity of pulmonary venous flow did 
not appear to increase with contrast injection by transesophageal 
Doppler but did appear to increase with transthoracic Doppler in 
the same patients tudied under similar conditions suggests hat 
the apparent increase in the transthoracic setting relates to 
technical rather than biologic factors. We can propose, for 
example, that his effect is the same as that observed by Forsberg 
et al. (22) when measuring flow velocities invitro before and after 
contrast administration: By increasing the number of scatterers 
and therefore the power of the returning Doppler signal, the 
amplitude of the underlying velocity spectrum isincreased so that 
more of the spectrum exceeds the display threshold, producing an 
apparent increase in velocity. This contention isfurther supported 
by the observation that contrast administration did not produce 
an increase in velocities with transesophageal Doppler, implying 
no actual change in blood flow velocity. Our findings uggest that 
although contrast enhances weaker Doppler signals, there is no 
effect on the velocities of optimal strength Doppler signals, as 
recorded at close range with transesophageal pulsed Doppler. 
The increase in transthoracic velocities appeared to affect 
all components of the pulmonary venous flow proportionally, 
as evidenced by the lack of change in peak flow velocity ratios. 
This finding provides reassurance that contrast-enhanced p ak 
flow velocity ratios can be utilized similarly to the unenhanced 
profiles to assess mitral regurgitation severity and left atrial 
pressure (5,8). 
Limitations of the study. During the present study, we did 
not perform invasive hemodynamic monitoring to evaluate the 
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immediate possible effects of Albunex injection on cardiac 
output. An increase in this variable would result in an increase 
in pulmonary venous flow, which would produce an increase in 
pulmonary venous Doppler velocities. However, previous tud- 
ies (23,24) using intracoronary injection of Albunex in animals 
and humans have shown no significant effects on systemic and 
left ventricular hemodynamic variables. We found no increase 
in pulmonary velocities after contrast injection when assessed 
by transesophageal pulsed Doppler echocardiography, suggest- 
ing that pulmonary flow was unchanged (assuming no change 
in pulmonary artery cross-sectional rea). 
Clinical implications. Analysis of the transthoracic pulmo- 
nary venous flow profile is a well established adjunctive Doppler 
assessment forconditions ranging from pericardial disease (25) to 
left ventricular systolic and diastolic function (26). Because of the 
ease of administration of intravenous sonicated albumin, this 
agent provides the opportunity, for improved evaluation of the 
pulmonary venous flow profile and provides levels of accuracy 
similar to transesophageal valuation. 
Because pulmonary venous flow is best evaluated in the 
latter part of the contrast injection, there is an opportunity 
(-30 s) to evaluate other aspects of cardiac function in the 
early part of the injection. Evaluation of left ventricular 
function with contrast-enhanced two-dimensional echocardi- 
ography or assessment ofvalvular egurgitation with contrast- 
enhanced color Doppler echocardiography can be undertaken. 
Our initial experience suggests hat sonicated albumin contrast 
agent may not significantly enhance the pulmonary venous flow 
Doppler signal in patients with severe obstructive pulmonary 
disease and pulmonary hypertension. 
Conclusions. Transthoracic echocardiography with intra- 
venous onicated albumin improves the quality of the pulmo- 
nary venous Doppler signal. Biphasic systolic waves are visu- 
alized as easily as with transesophageal echocardiography. 
Peak flow velocities obtained after contrast injection compare 
well with transesophageal velocities, and flow velocity ratios 
are not altered. Intravenous administration of Albunex for 
enhancement of Doppler signals is an effective method of 
increasing the quality of data obtained from the transthoracic 
echocardiographic examination. 
We thank Robert A. Lcvinc. MD, for thought-provoking discussions and helpful 
comments. 
References 
1. Keren G, Sherez J, Megidish R. Levitt B, Laniado S. Pulmonary, venous flow 
pattern--its relationship to cardiac dynamics. A pulsed Doppler echocardio- 
graphic study. Circulation 1985;71:11(15-12. 
2. Rossvoll O, Hatle LK. Pulmonary venous flow velocities recorded by 
transthoraeic Doppler ultrasound: relation to left ventricular diastolic pres- 
sures. J Am Coil Cardiol 1993:21:1687-96. 
3. Kuecherer HF, Kusumoto F. Muhiudcen IA, Cahalan MK, Schiller NB. 
Pulmonary venous flow patterns by transesophageal pu sed Doppler echo- 
cardiography: relation to parameters of left vcntricular systolic and diastolic 
function. Am Heart J 1991;122:1683-93. 
4. Klein AL, Hatle LK~ Bursto~ DJ. ct al. Doppler characterization f left 
ventricular diastolic function in cardiac amyloidosis. J Am Coil Cardiol 
1989;13:1017-26. 
5. Klein AL, Stewart WJ, Bartlett J, et al. Effects of mitral regurgitation of
pulmonary venous flow and left atrial pressure: an intraoperative transesoph- 
ageal echocardiographic study. J Am Coil Cardiol 1992;20:1345-52. 
6. Klein AL, Bailey AS, Cohen GI, et al. Effects of mitral stenosis on 
pulmonary venous flow as measured by Doppler transesophageal chocar- 
diography. Am J Cardiol 1993;72:66-72. 
7. Kuecherer HF, Muhiudeen IA, Kusumoto FM, et al. Estimation of mean left 
atrial pressure from transesophageal pulsed Doppler echocardiography of 
pulmonary venous flow. Circulation 1990;82:1127-39. 
8. Masuyama T, Lee J-M, Nagano R, et al. Doppler echocardiographic 
pulmonary venous flow-velocity pattern for assessment of the hemodynamic 
profile in acute congestive heart failure. Am Heart J 1995;129:107-13. 
9. Smallhorn JF, Freedom RM. Pulsed Doppler echocardiography in the 
preoperative evaluation of total anomalous pulmonary venous connection. 
J Am Coil Cardiol 1986;8:1413-20. 
ll). Castello R, Pearson AC, Lenzen P, Labovitz AJ. Evaluation of pulmonary 
venous flow by transesophageal chocardiography in subjects with a normal 
heart: comparison with transthoracic e hoeardiography. J Am Coll Cardiol 
199l;18:65-71. 
11. Klein AL, Burstow D J, Tajik AJ, Zachariah PK, Bailey KR, Seward JB. 
Effects of age on left ventricular dimensions and filling dynamics in 117 
normal persons. Mayo Clin Proc 1994;69:212-24. 
12. Keller MW, Segal SS, Kaul S, Duling B. The behavior of sonicated albumin 
microbubbles within the microcirculation: a basis for their use during 
myocardial contrast echocardiography. Circ Res 1989;65:458-67. 
13. Keller MW, Glasheen W, Teja K, Gear A, Kaul S. Myocardial contrast 
echocardiography without significant hemodynamic effects or reactive hy- 
peremia: amajor advantage inthe imaging of regional myocardial perfusion. 
J Am Coil Cardiol 1988;12:1039-47. 
14. Feinstein SB, Cheirif J, Ten Care FJ, et al. Safety and efficacy of a new 
transpulmonary ultrasound contrast agent: initial multicenter clinical results. 
J Am Coil Cardiol 1990;16:316-24. 
15. l'anabe K, Yoshitomi H, Oyake N, et al. Effects of supine and lateral recumbent 
positions on pulmonary venous flow in healthy subjects evaluated by transesoph- 
ageal Doppler echocardiography. J Am Coil Cardiot 1994;24:1552-7. 
16. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Relation of pulmonary vein 
to mitral flow velocities by transesophageal Doppler echocardiography. 
Effect of different loading conditions. Circulation 1990;81:1488-97. 
17. Wcyman AE. Principles and Practice of Echocardiography. Philadelphia: 
Lea & Fcbiger, 1994:163-83. 
18. Smallhorn JF, Freedom RM, OUey PM. Pulsed Doppler echocardiographic 
assessment of extraparcnchymal pulmonary vein flow. J Am Coll Cardiol 
1987 ;9:573-9. 
19. Masuyama T, Lee J-M, Tamai M, Tanouchi J, Kitabatake A, Kamada T. 
Pulmonary venous flow velocity pattern as assessed with transthoracic pulsed 
Doppler cchocardiography in subjects without cardiac disease. Am J Cardiol 
199 l;67:1396-14(14. 
20. Padial LR, Chen MH, Vuille C, Guerrcro JL, Weyman AlE, Picard MH. 
Pulsatile pressurc affects the disappearance of echocardiographic contrast 
agents. J Am Soc Echocardiogr 1995;8:285-92. 
21. Masuyama T, Nagano R, Nariyama K, et al. Transthoracic Doppler echocar- 
diographic measurements of pulmonary venous flow velocity patterns: compar- 
ison with transesophageal measurements. J Am Soc Echocardiogr 1995;8:61-9. 
22. Forsbcrg F, Liu J-B, Burns PN, Merton DA, Goldberg BB. Artifacts in 
ultrasonic ontrast agent studies. J Ultrasound Med 1994;13:357-65. 
23. Keller MW, Glasheen W, Kaul S. Albunex: a safe and effective commercially 
produced agent for myocardial contrast echocardiography. J Am Soc Echo- 
cardiogr 1989;2:48-52. 
24. Ten Cale F J, Widimsky P, Cornel JH, Waldstein D J, Serruys PW, Waaler A. 
lntracoronary Albunex: its effects on left ventricular hemodynamics, func- 
tiun, and coronary' sinus flow in humans. Circulation 1993;88:2123-7. 
25. Hatlc LK, Appleton CP, Popp RL. Differentiation fconstrictive pericarditis 
and restrictive cardiomyopathy b Doppler echocardiography. Circulation 
1989;79:357-7(t. 
26. Nagano R, Masuyama T, Lee J-M, et al. Transthoracic Doppler assessment 
of pattern of left ventricular dysfunction in hypertensive heart disease: 
combined analysis of mitral and pulmonary, venous flow velocity patterns. J 
Am Soc Echocardiogr 1994;7:493-505. 
